PHILADELPHIA — Eurand is offering a new licensing opportunity for retailers and health care companies with AdvaTab Acetaminophen, an orally disintegrating tablet (ODT) that incorporates its proprietary AdvaTab ODT and Microcaps taste-masking technologies.
The specialty pharmaceutical firm said AdvaTab Acetaminophen is an immediate-release product formulated in a range of dosing strengths (80 mg to 500 mg) for children and adults. Given that the acetaminophen formulation complies with the USP monograph, scale-up to launch could be completed for a partner in as little as six months, according to the company.
Eurand noted that new dosage forms in the over-the-counter health products category have proved popular with consumers, including children (chewables and mini-melts forms) as well as adults (thin films/strips and crystal forms).
The AdvaTab ODTs are a convenient, easy-to-swallow dosage form that can be taken with or without water, disintegrate within 30 seconds, and can be packaged in bottles or child-resistant blisters, and the incorporation of Eurand’s Microcaps taste-masking technology and flavoring deliver pleasant-tasting tablets.
Recent commercialized products that leverage Eurand’s technologies include Chattem’s Unisom SleepMelts (diphenhydramine HCl) sleep aid ODTs, which have a cherry flavor, and GlaxoSmithKline’s Lamictal ODT (lamotrigine) anti-epileptic pills, which have a fruity taste.
